(Reuters) - BRUSSELS, April 26 - Belgian pharmaceutical group UCB is performing well and its results this year are so far in line with expectations, Chief Executive Roch Doliveux said on Thursday.
UCB previously said revenues and operating profit were expected to grow significantly in 2007 as a result of its acquisition of German peer Schwarz.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment